A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes
暂无分享,去创建一个
J. McCubrey | S. Paolini | A. Pession | P. Suh | C. Finelli | A. Astolfi | J. Boultwood | A. Pellagatti | L. Manzoli | S. Mongiorgi | Stefano Ratti | M. Cavo | M. Follo | V. Indio | S. Parisi | A. de Stefano | L. Cocco | Irene Casalin
[1] Annette S. Kim,et al. miR-378-3p Knockdown Recapitulates Many of the Features of Myelodysplastic Syndromes. , 2021, The American journal of pathology.
[2] S. Lim,et al. TET2 Mutation and High miR-22 Expression as Biomarkers to Predict Clinical Outcome in Myelodysplastic Syndrome Patients Treated with Hypomethylating Therapy , 2021, Current issues in molecular biology.
[3] Ming Yao,et al. LncRNA CD27-AS1 promotes acute myeloid leukemia progression through the miR-224-5p/PBX3 signaling circuit , 2021, Cell Death & Disease.
[4] A. Alfonso-Pierola,et al. Current Therapy of the Patients with MDS: Walking towards Personalized Therapy , 2021, Journal of clinical medicine.
[5] Qinghua Li,et al. Circular RNA circ_0005774 contributes to proliferation and suppresses apoptosis of acute myeloid leukemia cells via circ_0005774/miR-192-5p/ULK1 ceRNA pathway. , 2021, Biochemical and biophysical research communications.
[6] Yao Yao,et al. Emerging Role of MiR-192-5p in Human Diseases , 2021, Frontiers in Pharmacology.
[7] Heather J. Lee,et al. Unravelling the Epigenome of Myelodysplastic Syndrome: Diagnosis, Prognosis, and Response to Therapy , 2020, Cancers.
[8] B. Seliger,et al. Expression, Regulation and Function of microRNA as Important Players in the Transition of MDS to Secondary AML and Their Cross Talk to RNA-Binding Proteins , 2020, International journal of molecular sciences.
[9] Dapeng Sun,et al. Identifying of miR-98-5p/IGF1 axis contributes breast cancer progression using comprehensive bioinformatic analyses methods and experiments validation. , 2020, Life sciences.
[10] A. Goldberg,et al. Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure. , 2020, Blood advances.
[11] M. Caligiuri,et al. Combined loss of function of two different loci of miR-15/16 drives the pathogenesis of acute myeloid leukemia , 2020, Proceedings of the National Academy of Sciences.
[12] Duncan Ayers,et al. Overview of current microRNA biomarker signatures as potential diagnostic tools for leukaemic conditions , 2020, Non-coding RNA research.
[13] C. Croce,et al. MicroRNA dysregulation and multi-targeted therapy for cancer treatment. , 2020, Advances in biological regulation.
[14] Fei Wang,et al. miRTarBase 2020: updates to the experimentally validated microRNA–target interaction database , 2019, Nucleic Acids Res..
[15] Xiaowei Wang,et al. miRDB: an online database for prediction of functional microRNA targets , 2019, Nucleic Acids Res..
[16] H. Chung,et al. miR-222 represses expression of zipcode binding protein-1 and phospholipase C-γ1 in intestinal epithelial cells. , 2019, American journal of physiology. Cell physiology.
[17] M. Gobbi,et al. Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes , 2019, Leukemia.
[18] C. Craddock,et al. Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] B. Feinberg,et al. Treatment sequence of lenalidomide and hypomethylating agents and the impact on clinical outcomes for patients with myelodysplastic syndromes , 2019, Leukemia & lymphoma.
[20] P. Hrelia,et al. Meripilus giganteus ethanolic extract exhibits pro-apoptotic and anti-proliferative effects in leukemic cell lines , 2018, BMC Complementary and Alternative Medicine.
[21] J. McCubrey,et al. Nuclear phospholipase C isoenzyme imbalance leads to pathologies in brain, hematologic, neuromuscular, and fertility disorders[S] , 2018, Journal of Lipid Research.
[22] Yu-Chiao Chiu,et al. The prognostic significance of global aberrant alternative splicing in patients with myelodysplastic syndrome , 2018, Blood Cancer Journal.
[23] Yu-Chiao Chiu,et al. The prognostic significance of global aberrant alternative splicing in patients with myelodysplastic syndrome , 2018, Blood Cancer Journal.
[24] F. Gao,et al. Downregulation of microRNA-21 expression inhibits proliferation, and induces G1 arrest and apoptosis via the PTEN/AKT pathway in SKM-1 cells , 2018, Molecular medicine reports.
[25] Jun Lu,et al. MicroRNA-192 regulates cell proliferation and cell cycle transition in acute myeloid leukemia via interaction with CCNT2 , 2017, International Journal of Hematology.
[26] Dongshan Zhang,et al. p53 activates miR-192-5p to mediate vancomycin induced AKI , 2016, Scientific Reports.
[27] M. Rossi,et al. miRNA-Mediated KHSRP Silencing Rewires Distinct Post-transcriptional Programs during TGF-β-Induced Epithelial-to-Mesenchymal Transition. , 2016, Cell reports.
[28] William A. Rennie,et al. STarMirDB: A database of microRNA binding sites , 2016, RNA biology.
[29] J. McCubrey,et al. Selective Activation of Nuclear PI-PLCbeta1 During Normal and Therapy-Related Differentiation. , 2016, Current pharmaceutical design.
[30] C. Finelli,et al. An increased expression of PI‐PLCβ1 is associated with myeloid differentiation and a longer response to azacitidine in myelodysplastic syndromes , 2015, Journal of leukocyte biology.
[31] Jiasun Lu,et al. Regulation of growth of human bladder cancer by miR-192 , 2015, Tumor Biology.
[32] Luca Malcovati,et al. Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.
[33] S. Paolini,et al. Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients , 2012, Leukemia.
[34] M. Gobbi,et al. Epigenetic regulation of nuclear PI-PLCbeta1 signaling pathway in low-risk MDS patients during azacitidine treatment , 2012, Leukemia.
[35] L. Cocco,et al. The physiology and pathology of inositide signaling in the nucleus , 2011, Journal of cellular physiology.
[36] A. Martelli,et al. Nuclear inositide signaling in myelodysplastic syndromes , 2010, Journal of cellular biochemistry.
[37] M Cazzola,et al. Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells , 2010, Leukemia.
[38] M. Baccarani,et al. Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS , 2009, Proceedings of the National Academy of Sciences.
[39] Aimee L Jackson,et al. Coordinated regulation of cell cycle transcripts by p53-Inducible microRNAs, miR-192 and miR-215. , 2008, Cancer research.
[40] C. Burge,et al. Most mammalian mRNAs are conserved targets of microRNAs. , 2008, Genome research.
[41] C. Finelli,et al. Real-time PCR as a tool for quantitative analysis of PI-PLCbeta1 gene expression in myelodysplastic syndrome. , 2006, International journal of molecular medicine.
[42] B. Cheson,et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.
[43] Li Wang,et al. Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype. , 2006, Blood.
[44] Stijn van Dongen,et al. miRBase: microRNA sequences, targets and gene nomenclature , 2005, Nucleic Acids Res..
[45] A. Martelli,et al. Nuclear inositol lipid metabolism: More than just second messenger generation? , 2005, Journal of cellular biochemistry.
[46] A. Martelli,et al. Nuclear phospholipase C signaling through type 1 IGF receptor and its involvement in cell growth and differentiation. , 2005, Anticancer research.
[47] A. Martelli,et al. Metabolism and signaling activities of nuclear lipids , 2004, Cellular and Molecular Life Sciences CMLS.
[48] A. Martelli,et al. Up‐regulation of nuclear PLCβ1 in myogenic differentiation , 2003 .
[49] N. Harris,et al. The World Health Organization (WHO) classification of the myeloid neoplasms. , 2002, Blood.
[50] C. Vasselon,et al. Expression and prognostic significance of Bcl‐2 family proteins in myelodysplastic syndromes , 2002, American journal of hematology.
[51] G. Mufti,et al. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. , 2000, Blood.
[52] R. Davis,et al. Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: relation to disease progression. , 1998, Leukemia research.
[53] Y. Zhang,et al. MicroRNA-124 inhibits colorectal cancer cell proliferation and suppresses tumor growth by interacting with PLCB1 and regulating Wnt/β-catenin signaling pathway. , 2019, European review for medical and pharmacological sciences.
[54] Yue Zhai,et al. miR-423-5p inhibits the proliferation and metastasis of glioblastoma cells by targeting phospholipase C beta 1. , 2019, International journal of clinical and experimental pathology.
[55] Xiaohua Li,et al. Low miR-192 expression predicts poor prognosis in pediatric acute myeloid leukemia. , 2018, Cancer biomarkers : section A of Disease markers.
[56] Y. Suh,et al. Phospholipase D1 Acts through Akt/TopBP1 and RB1 to Regulate the E2F1-Dependent Apoptotic Program in Cancer Cells. , 2017, Cancer research.
[57] J. McCubrey,et al. PLC-β1 and cell differentiation: An insight into myogenesis and osteogenesis. , 2017, Advances in biological regulation.
[58] A. Martelli,et al. Nuclear phospholipase C beta1 and cellular differentiation. , 2008, Frontiers in bioscience : a journal and virtual library.
[59] Hilde van der Togt,et al. Publisher's Note , 2003, J. Netw. Comput. Appl..
[60] A. Martelli,et al. Up-regulation of nuclear PLCbeta1 in myogenic differentiation. , 2003, Journal of cellular physiology.